{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T04:18:49Z","timestamp":1787545129462,"version":"build-2736575974"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"DOI":"10.1186\/s40364-026-00990-4","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T03:31:10Z","timestamp":1787542270000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["HIRA loss is frequent but not universal in human fumarate hydratase-deficient renal cell carcinoma and defines divergent oncogenic programs"],"prefix":"10.1186","volume":"14","author":[{"given":"Xu","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehua","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangxi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"issue":"6","key":"990_CR1","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1158\/1078-0432.CCR-20-3788","volume":"27","author":"G Sun","year":"2021","unstructured":"Sun G, Zhang X, Liang J, Pan X, Zhu S, Liu Z, et al. Integrated molecular characterization of fumarate hydratase\u2013deficient renal cell carcinoma. Clin Cancer Res. 2021;27(6):1734\u201343. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3788.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"990_CR2","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1016\/j.juro.2007.01.155","volume":"177","author":"RL Grubb","year":"2007","unstructured":"Grubb RL, Franks ME, Toro J, Middelton L, Choyke L, Fowler S, et al. Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J Urol. 2007;177(6):2074\u201380; discussion 2079\u20132080 (https:\/\/doi.org\/10.1016\/j.juro.2007.01.155.","journal-title":"J Urol"},{"issue":"1","key":"990_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.molmed.2016.12.001","volume":"23","author":"GM Fuhler","year":"2017","unstructured":"Fuhler GM, Eppinga H, Peppelenbosch MP. Fumarates and cancer. Trends Mol Med. 2017;23(1):3\u20135. https:\/\/doi.org\/10.1016\/j.molmed.2016.12.001.","journal-title":"Trends Mol Med"},{"issue":"7621","key":"990_CR4","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature19353","volume":"537","author":"M Sciacovelli","year":"2016","unstructured":"Sciacovelli M, Gon\u00e7alves E, Johnson TI, Zecchini VR, da Costa ASH, Gaude E, et al. Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition. Nature. 2016;537(7621):544\u201347. https:\/\/doi.org\/10.1038\/nature19353.","journal-title":"Nature"},{"issue":"7","key":"990_CR5","doi-asserted-by":"publisher","first-page":"880","DOI":"10.3390\/metabo13070880","volume":"13","author":"S Giallongo","year":"2023","unstructured":"Giallongo S, Costa F, Longhitano L, Giallongo C, Ferrigno J, Tropea E, et al. The pleiotropic effects of fumarate: from mitochondrial respiration to epigenetic rewiring and DNA repair mechanisms. Metabolites. 2023;13(7):880. https:\/\/doi.org\/10.3390\/metabo13070880.","journal-title":"Metabolites"},{"key":"990_CR6","doi-asserted-by":"publisher","unstructured":"Valcarcel-Jimenez L, Rogerson C, Yong C, Schmidt C, Yang M, Cremades-Rodelgo M, et al. HIRA loss transforms FH-deficient cells. Sci Adv. 2022;8(42):eabq8297. https:\/\/doi.org\/10.1126\/sciadv.abq8297.","DOI":"10.1126\/sciadv.abq8297"},{"issue":"10","key":"990_CR7","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1158\/1078-0432.CCR-20-4367","volume":"27","author":"JP Gleeson","year":"2021","unstructured":"Gleeson JP, Nikolovski I, Dinatale R, Zucker M, Knezevic A, Patil S, et al. Comprehensive molecular characterization and response to therapy in fumarate hydratase\u2013deficient renal cell carcinoma. Clin Cancer Res. 2021;27(10):2910\u201319. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4367.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"990_CR8","doi-asserted-by":"publisher","first-page":"4398","DOI":"10.1038\/s41467-025-59513-8","volume":"16","author":"X Zhang","year":"2025","unstructured":"Zhang X, Zhao J, Yin X, Liang J, Wang Y, Zheng L, et al. Comprehensive molecular profiling of FH-deficient renal cell carcinoma identifies molecular subtypes and potential therapeutic targets. Nat Commun. 2025;16(1):4398. https:\/\/doi.org\/10.1038\/s41467-025-59513-8.","journal-title":"Nat Commun"},{"issue":"7","key":"990_CR9","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.tcb.2024.04.009","volume":"34","author":"KM Kiang","year":"2024","unstructured":"Kiang KM, Ahad L, Zhong X, Lu QR. Biomolecular condensates: hubs of hippo-YAP\/TAZ signaling in cancer. Trends Cell Biol. 2024;34(7):566\u201377. https:\/\/doi.org\/10.1016\/j.tcb.2024.04.009.","journal-title":"Trends Cell Biol"},{"issue":"13","key":"990_CR10","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.18632\/oncotarget.27988","volume":"12","author":"SS Dhar","year":"2021","unstructured":"Dhar SS, Lee MG. Cancer-epigenetic function of the histone methyltransferase KMT2D and therapeutic opportunities for the treatment of KMT2D-deficient tumors. Oncotarget. 2021;12(13):1296\u2013308. https:\/\/doi.org\/10.18632\/oncotarget.27988.","journal-title":"Oncotarget"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-00990-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-026-00990-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-00990-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T03:31:12Z","timestamp":1787542272000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40364-026-00990-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["990"],"URL":"https:\/\/doi.org\/10.1186\/s40364-026-00990-4","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"assertion":[{"value":"19 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review Board of West China Hospital, Sichuan University in compliance with the Declaration of Helsinki. The tissue samples were obtained with written informed consent was obtained from each patient to allow the use of his\/her samples and data in research.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for informed consent for publication was waived due to the retrospective nature of the study and the use of de-identified data.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"92"}}